Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
THC Therapeutics, Inc. (THCT)
Las Vegas, NV, US
THC Therapeutics, Inc. is a company active in the wellness sector, primarily engaged in developing the dHydronator. This innovative device functions as a sanitizing herb dryer, specifically designed for the efficient drying and cleansing of freshly harvested cannabis, as well as a variety of other herbs, flowers, and tea leaves. Established in 2007, the organization was initially known as Millennium Blockchain, Inc. before officially changing its name to THC Therapeutics, Inc. in September 2018. The company's corporate headquarters are located in Las Vegas, Nevada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +55.56% | +40.00% | +600.00% | +1,300.00% | +1,300.00% | +6,900.00% | -20.00% | -89.68% | -89.68% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+74.2% ★ Q2'24: -6.9% (vs Q2'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q2'24: -17.6% (vs Q2'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-1.3% ★ Q2'24: +17.1% (vs Q2'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.61× Q2'24: 1.48× (vs Q2'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Brunson Chandler & Jones, PLLC | 1.50M | 6.30% | 1.50M | — | 1.50M | — | PN | Utah | 2020-10-29 | ↗ |
| 2 | Callie Jones | 1.50M | 6.30% | — | 1.50M | — | 1.50M | IN | United States | 2020-10-29 | ↗ |
| 3 | Lance Brunson | 1.50M | 6.30% | — | 1.50M | — | 1.50M | IN | United States | 2020-10-29 | ↗ |
| 4 | Y. Chase Chandler | 1.50M | 6.30% | — | 1.50M | — | 1.50M | IN | United States | 2020-10-29 | ↗ |
| 5 | Fife Trading, Inc.36-4151891 | 1.48M | 9.99% | 1.48M | — | 1.48M | — | CO | — | 2020-02-14 | ↗ |
| 6 | Iliad Management, LLC20-0411071 | 1.48M | 9.99% | 1.48M | — | 1.48M | — | OO | — | 2020-02-14 | ↗ |
| 7 | Iliad Research & Trading, L.P.11-3688679 | 1.48M | 9.99% | 1.48M | — | 1.48M | — | PN | — | 2020-02-14 | ↗ |
| 8 | John M. Fife | 1.48M | 9.99% | 1.48M | — | 1.48M | — | IN | — | 2020-02-14 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013-11-14 | TANAKA HIRO | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-09-10 | Smith Adrian J R | Director / Officer | — | D | Stock Options | 1,000,000 | 0.03 | 27.5K | 0 | — | ↗ |
| 2013-09-10 | MANN JAMIE | Director / Officer / 10% Owner | — | D | Stock Options | 6,403,726 | 0.03 | 176.1K | 0 | — | ↗ |
| 2010-06-07 | Ho Eden | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 0.42 | 2.1K | 24,001 | — | ↗ |
| 2010-05-28 | Ho Eden | Director / Officer | P-Purchase | A | Common Stock | 19,001 | 0.52 | 9.9K | 19,001 | — | ↗ |
| 2010-03-15 | Ho Eden | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Scott Cox | President, CEO, CFO & Director | — | male |
| Victor Nacif | Head of Design | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for THCT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
